Summary of 2022
2021 was the year when a great deal of what Inven2 has long been working towards finally bore fruit. It takes a long time to commercialise basic research, and it is therefore important to have faith that the processes involved and the expertise invested in them will produce results.
Gain insight into the year that passed through success stories and key figures.
Latest news
More news
Latest news
Here you can read the latest news regarding Inven2s portfolio businesses, innovation projects and clinical studies. Every month we write longer articles where we interview current researchers and clinicians.
Will revolutionise CAR-T therapy with a Norwegian licence
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by...
Vital licences
Inven2 has long experience of licence agreements, particularly in life sciences, which dominate the portfolio. The available licences are presented...
A unique biological super-taxi has been developed
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
Events
More events
Events
Licensing opportunities
All licensing opportunities
Licensing opportunities
Here you will find an overview of license opertunities. We are actively looking for industry partners who may consider licensing these technologies to further develop them into products or services.
Therapeutic regulation of WNT/YAP-signaling through a potent and specific tankyrase inhibitor
A class of novel WNT/YAP inhibitor compounds exhibiting high specificity for tankyrase and demonstrated proof of concept in mouse models for several cancer indications. Read more
An optimized engineered albumin for half-life extension and mucosal delivery of biologics
An engineered human albumin variant with extended in vivo half-life. Read more
A versatile improved antibody Fc technology platform
A unique and versatile antibody Fc technology platform (“REW”). Read more
AnaConDebt – Analysis of Contagious technical Debt
Technical debt in software development consists of sub-optimal design solutions that are beneficial in the short term, but create costly negative impact in the long run, e.g. costly maintenance changes and impossibility to evolve the system. Read more
Innovation
Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.
Clinical studies
Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.
Key figures 2010 – 2022
# Ideas evaulated (DOFI)
# Companies established
# Licence agreements
# New patent applications
MNOK transferred back to research, innovation and inventors
# Clinical Trials managed
Portfolio businesses
More businesses
Portfolio businesses
Inven2 has a portfolio comprising 53 companies. We have established them either on our own or alongside investors to commercialise research results from innovative researchers. The point of departure for the companies are research results from innovative researchers. The portfolio value in October 2020 is NOK 23 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.
Products on the market
More products
Products on the market
Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.
EPISHUTTLE – Transport isolator
Photo: EpiGuard
QUEST 5 HMC DNA ELISA KIT Epigenetic kit
Photo: Zymo Research
PROBNP – Heart disease test
Photo: Roche
